ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Zoom Video Communications Inc

Zoom Video Communications Inc (1ZM)

66.61
0.00
( 0.00% )
업데이트: 23:00:11

개인 투자자를 위한 전문가급 도구.

1ZM 뉴스

공식 뉴스 전용
Bigtrade PT Bigtrade PT 4 분 전
I don't believe in this climb... it's going to fall more...
ELAB
$treet Trader $treet Trader 4 분 전
Good morning A$ & LD
Screech691 Screech691 4 분 전
love SGTM's commitment to sustainability with their living mulch product
COMMITTED TO SUSTAINABILITY
Microbe Living Mulch delivers impressive outcomes for your landscape, including enhanced aesthetic appeal and increased yields for healthier gardens. It aids in carbon sequestration, im
SGTM
02opida 02opida 5 분 전
VOTE America
$treet Trader $treet Trader 5 분 전
Good morning .0001ers
JettaR JettaR 5 분 전
Poor abandoned child. 
CBDW
getmoreshares getmoreshares 5 분 전
https://x.com/woofknight/status/1853787152342999283
Midwestrader Midwestrader 5 분 전
Evidently that CLOWN CAR CEO never really did DD and research on what happens with the pps after a REVERSE SPLIT. He probably thought it would drop a few cents and he'd be DUMPING away at say....0.35. 🤣 🤪

Nah...this POS CON JOB SHAM is now down 78.94% as of close yest
INND
docj docj 5 분 전
New SAB member:
Clinton Yam, MD, MS
Dr. Clinton Yam is an Associate Professor with dual appointments in the Departments of Breast Medical Oncology and Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. Dr. Yam is leader of the triple-negative breast
CYDY
02opida 02opida 5 분 전
Good Morning America
BigBadWolf BigBadWolf 5 분 전
$ASIInvestors Learned long ago [yt]Wxk1cyYJe-o[/yt]
My $ I base it's use on my DD & highly recommend both the aforementioned to all
ASIINVESTO
getmoreshares getmoreshares 5 분 전
https://x.com/woofknight/status/1853787152342999283
StayHumble StayHumble 5 분 전
🚩🚩 Hearing there’s a Massive Reverse Split 🚩🚩Coming
https://i.imgflip.com/7idht1.jpg
DJT
jjjjjjjj jjjjjjjj 5 분 전
Good buys of 28M shares but only last minute buys will work! All short sellers have no more shares to borrow. They fake the shares by claiming settlement days. Keep doing
1. SET SELL HIGH our shares,
2. SET BUY HIGH at last minute with price limit.
Our time will come unst
MJNA
Eli's Gone Eli's Gone 5 분 전
sure LOL---and the Chevys weren't blocking for Byron and Bubba "thinks" something broke just before he allowed fellow Toyota driver Bell to pass him for the crucial 1 point needed....

a few peeps might pay after NASCAR goes over the radio traffic among those teams involved
SHEEPWOLF SHEEPWOLF 6 분 전
$ILLR AMONG PREMARKET GAINERS
#TRILLER IS READY TO TAKE OFF↗️
https://investorshub.advfn.com/uimage/uploads/2024/11/5/thfegGAINERS.png
ILLR
Mr.Wolf Mr.Wolf 6 분 전
oh contrar. Go to the Q3 management report and look at QoQ sales. Q2 growth was 400%, if you account for 1/3 of Q3 sales being offline the sales would have been approx: $358,000 ($236k/.66). which is 43% sales growth. People like and were buying the product. The challenge is how much customer loyalt
PSYCF
SHEEPWOLF SHEEPWOLF 6 분 전
$ILLR AMONG PREMARKET GAINERS
#TRILLER IS READY TO TAKE OFF↗️
https://investorshub.advfn.com/uimage/uploads/2024/11/5/thfegGAINERS.png
ILLR
docj docj 6 분 전
Who says they don't? We'll find out in due time. The trial does't start until early next year.
CYDY
TJG TJG 7 분 전
It seems there was an update on the Share Structure on Oct 23 Lets see if there are any differences and what they may be

OS is up 200 million and the unrestricted is up 20 million Held at DTC is the same

Oct 23

AFFU Security Details
Share Structur
AFFU DTC
TKS PARTY TKS PARTY 7 분 전
Any news at this point will be highly appreciated !!!!!!
CBRF
georgie18 georgie18 7 분 전
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented A
ALLO
GMH* GMH* 7 분 전
Link to abstract:
https://jitc.bmj.com/content/12/Suppl_3/A1718
Key take-away:

At a median follow-up of 25.6 months, the ORR (95% CI) in the EGFR-wt subgroup of interest for further studies was 64.3% (35.1%–87.2%). Median DOR in this subgroup was not reached (NR; 95% CI,
IOVA